-
BioPharma Dive – AI / Data2 weeks agoMerck’s deal for Terns sparks debate over a possible biotech bidding war
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: Denali Therapeutics, Corcept Therapeutics win FDA approvals
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA granted accelerated approval...
-
AI & Machine Learning in Biotechnology2 weeks agoHealth influencers talk social media and mental health
A jury in Los Angeles has found social media giants Google and Meta liable for the mental health struggles of a 20-year-old woman, awarding her $3...
-
BioPharma Dive – AI / Data2 weeks agoFDA clears Denali drug in ‘clear step’ for rare disease biotechs
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance...
-
Biotech Industry Intelligence2 weeks ago
Wave crashes on obesity disappointment
Wave crashes on obesity disappointment
-
Uncategorized2 weeks ago
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those receiving the higher dose saw...
-
AI & Machine Learning in Biotechnology2 weeks agoSTAT+: A surprise opening for health care reforms
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
BioPharma Dive – AI / Data2 weeks agoWave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second...
-
Uncategorized2 weeks agoGlobal collaboration aims to create safer cancer therapeutics
An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics. iXCells Biotechnologies, a provider of...
-
Endpoints News2 weeks ago
Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 program
Plus, news about Astellas’ setidegrasib and Anavex: 📈 Kodiak’s eye drug win: The biotech’s experimental drug Zenkuda, whose scientific name is tarcocimab tedromer, beat a sham...
High-Throughput Platform for Fast-Acting Covalent Protein Therapies
Terns rebuffed a higher bid before selling to Merck
